Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced ...

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings tomorrow after market close. Here’s what to look for. Supernus Pharmaceuticals beat analysts ...

ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

Detailed price information for Collegium Pharma (COLL-Q) from The Globe and Mail including charting and trades.

The market seems to believe in the growth potential of Supernus Pharmaceuticals and the stock has outperformed the sector. However, I think some uncertainty about a product's market prospects can ...

Invesco Ltd. lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the SEC.

Sei Investments Co. cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 5.4% during the fourth quarter, HoldingsChannel.com reports.

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results , with sales up 6% year on year to $174.2 million. On the other hand, the company’s full-year ...